{"id":551276,"date":"2026-04-01T22:50:07","date_gmt":"2026-04-01T20:50:07","guid":{"rendered":"https:\/\/medizinonline.com\/novos-padroes-terapeuticos-com-o-shr-a-1811\/"},"modified":"2026-04-01T22:50:44","modified_gmt":"2026-04-01T20:50:44","slug":"novos-padroes-terapeuticos-com-o-shr-a-1811","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/pt-pt\/novos-padroes-terapeuticos-com-o-shr-a-1811\/","title":{"rendered":"Novos padr\u00f5es terap\u00eauticos com o SHR-A 1811"},"content":{"rendered":"\n<p><strong>A edi\u00e7\u00e3o deste ano do Congresso ESMO 2025 voltou a oferecer uma vasta gama de novos dados sobre o tratamento do cancro da mama HER2-positivo, incluindo a an\u00e1lise intercalar do estudo HORIZON-Breast01 de fase 3 apresentada por Erwei Song (Universidade Sun Yat-sen, Guangzhou). O estudo compara o SHR-A 1811 com pirotinib mais capecitabina em doentes com cancro da mama HER2-positivo metast\u00e1tico. Fornece os primeiros dados aleat\u00f3rios sobre este novo conjugado anticorpo-f\u00e1rmaco direcionado para o HER2.  <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Fnovos-padroes-terapeuticos-com-o-shr-a-1811%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>A edi\u00e7\u00e3o deste ano do Congresso ESMO 2025 voltou a oferecer uma vasta gama de novos dados sobre o tratamento do cancro da mama HER2-positivo, incluindo a an\u00e1lise intercalar do&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Fnovos-padroes-terapeuticos-com-o-shr-a-1811%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":551279,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cancro da mama HER2+ com met\u00e1stases  ","footnotes":""},"category":[11521,11419,11379,11529,11551],"tags":[90029,13509,90026,17381,90042,22421,90018,90020,90036,90032,90023,90010,90015,90037,90013,90040],"powerkit_post_featured":[],"class_list":["post-551276","post","type-post","status-publish","format-standard","has-post-thumbnail","category-estudos","category-ginecologia-pt-pt","category-oncologia-pt-pt","category-relatorios-do-congresso","category-rx-pt","tag-analise-intercalar-estudo-de-fase-3-horizon-breast01","tag-cancro-da-mama","tag-cancro-da-mama-metastatico-her2-positivo","tag-capecitabina","tag-congresso-da-esmo-2025","tag-esmo-pt-pt","tag-estudo-de-fase-1-horizon-x","tag-estudo-pehdra","tag-estudo-phoebe","tag-novos-conjugados-anticorpo-farmaco-orientados-para-o-her2","tag-perfil-de-efeitos-secundarios-shr-a-1811-vs-pirotinib-capecitabina","tag-pirotinib","tag-pirotinib-mais-capecitabina","tag-sequenciacao-das-terapeuticas-dirigidas-ao-her2","tag-shr-a-1811","tag-shr-a1811-trastuzumab-rezetecan","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-28 02:09:45","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"pt_PT","wpml_translations":{"es_ES":{"locale":"es_ES","id":551287,"slug":"nuevos-estandares-terapeuticos-con-shr-a-1811","post_title":"Nuevos est\u00e1ndares terap\u00e9uticos con SHR-A 1811","href":"https:\/\/medizinonline.com\/es\/nuevos-estandares-terapeuticos-con-shr-a-1811\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/551276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=551276"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/551276\/revisions"}],"predecessor-version":[{"id":551281,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/551276\/revisions\/551281"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media\/551279"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=551276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/category?post=551276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=551276"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/powerkit_post_featured?post=551276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}